Last week’s developments in TB treatment included the announcement that bedaquiline, the currently most promising medicine for multi-drug-resistant tuberculosis, will become available to patients in 130 low- and middle-income countries through the Stop TB Partnership’s Global Drug Facility. That good news for multidrug-resistant TB patients, many of whom have run out of other options, was […]